Postoperative suppressive therapy for thyroid adenomas.

Area of Science:

• Endocrinology
• Surgical Oncology
• Thyroidology

Background:

• Partial thyroidectomy is frequently performed for follicular thyroid adenoma.
• Postoperative levothyroxine suppression therapy is commonly administered to prevent recurrence or new nodule formation.
• The clinical benefit and cost-effectiveness of this postoperative therapy remain uncertain.

Purpose of the Study:

• To evaluate the efficacy of postoperative thyroid suppression therapy in preventing new nodule development after partial thyroidectomy for follicular thyroid adenoma.
• To assess the impact of suppression therapy on patient costs.

Main Methods:

• Retrospective analysis of 76 patients who underwent partial thyroidectomy for follicular thyroid adenoma between 1985 and 1998.
• Patients were categorized based on the use of postoperative thyroid suppression therapy.
• Outcomes assessed included new thyroid nodule growth and reoperation rates, with a minimum follow-up of 6 months.

Main Results:

• The overall recurrence rate was 4% (3/76).
• No significant difference in new nodule development was observed between patients treated with (61%) and without postoperative suppression therapy (P = 0.274).
• Patients not receiving levothyroxine demonstrated significant cost savings, and no reoperations were required.

Conclusions:

• Postoperative thyroid suppression therapy may not be routinely indicated following partial thyroidectomy for follicular thyroid adenoma.
• The current findings suggest that withholding suppression therapy could lead to cost reductions without compromising patient outcomes.
• Further investigation via a prospective, randomized controlled trial is warranted to definitively establish the role of suppression therapy.